Giulia Cerretti
YOU?
Author Swipe
View article: TIP-05. Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: the MIRAGE trial
TIP-05. Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: the MIRAGE trial Open
BACKGROUND Meningiomas are the most common intracranial tumors. The role of systemic treatments remains poorly supported by evidence. Regorafenib is an oral multi-tyrosine kinase (RTK) inhibitor with high selectivity for VEGFR1/2/3. It als…
View article: CTNI-04. A PHASE 1, FIRST-IN-HUMAN STUDY OF REGORAFENIB PLUS TEMOZOLOMIDE WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED, IDH WILDTYPE GLIOBLASTOMA: THE REGOMA-2 TRIAL
CTNI-04. A PHASE 1, FIRST-IN-HUMAN STUDY OF REGORAFENIB PLUS TEMOZOLOMIDE WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED, IDH WILDTYPE GLIOBLASTOMA: THE REGOMA-2 TRIAL Open
BACKGROUND Regorafenib (REG) is an oral multikinase inhibitor that has shown synergistic antitumor effects with radiotherapy and temozolomide (TMZ) in glioblastoma. This phase 1 study evaluated the safety, dose-limiting toxicity (DLT), max…
View article: P12.32.A MOLECULAR STRATIFICATION BY PTEN STATUS REVEALS DIFFERENTIAL SECOND-LINE THERAPY RESPONSES IN RECURRENT IDH-WILDTYPE GLIOBLASTOMA
P12.32.A MOLECULAR STRATIFICATION BY PTEN STATUS REVEALS DIFFERENTIAL SECOND-LINE THERAPY RESPONSES IN RECURRENT IDH-WILDTYPE GLIOBLASTOMA Open
BACKGROUND Recurrent IDH-wildtype glioblastoma (rGBM) has a poor prognosis, and second-line therapies (i.e. nitrosoureas, regorafenib, bevacizumab) offer limited benefit. No clinical or molecular factors have been validated as predictors t…
View article: P12.21.B A PHASE 1, FIRST-IN-HUMAN STUDY OF REGORAFENIB PLUS TEMOZOLOMIDE WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED, IDH WILDTYPE GLIOBLASTOMA: REGOMA-2 TRIAL
P12.21.B A PHASE 1, FIRST-IN-HUMAN STUDY OF REGORAFENIB PLUS TEMOZOLOMIDE WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED, IDH WILDTYPE GLIOBLASTOMA: REGOMA-2 TRIAL Open
BACKGROUND Regorafenib (REG) is an oral multikinase inhibitor. In vivo studies demonstrated a synergistic antitumor effect when combined with radiotherapy (RT) and temozolomide (TMZ) against glioblastoma (GBM). We conducted a phase 1 study…
View article: P13.14.A REGORAFENIB VERSUS LOCAL STANDARD OF CARE IN PATIENTS WITH GRADE 2-3 MENINGIOMA NO LONGER ELIGIBLE FOR LOCO-REGIONAL TREATMENTS: THE MIRAGE TRIAL
P13.14.A REGORAFENIB VERSUS LOCAL STANDARD OF CARE IN PATIENTS WITH GRADE 2-3 MENINGIOMA NO LONGER ELIGIBLE FOR LOCO-REGIONAL TREATMENTS: THE MIRAGE TRIAL Open
BACKGROUND Meningiomas are the most common intracranial tumors. Standard treatment involves surgical resection with curative intent. When gross total resection is not achievable, or in case of recurrence, RT is frequently utilized. On the …
View article: P17.40.B EFFECTIVENESS OF TARGET THERAPY IN ADULT AND PEDIATRIC RECURRENT HIGH GRADE GLIOMA PATIENTS WITH BRAFV600E MUTATION OR NTRK FUSION: A REAL-LIFE MULTICENTRIC ITALIAN ANALYSIS.
P17.40.B EFFECTIVENESS OF TARGET THERAPY IN ADULT AND PEDIATRIC RECURRENT HIGH GRADE GLIOMA PATIENTS WITH BRAFV600E MUTATION OR NTRK FUSION: A REAL-LIFE MULTICENTRIC ITALIAN ANALYSIS. Open
BACKGROUND Although the BRAFV600E mutation and NRTK-fusion are rare entities in high-grade glioma (HGG) patients (Pts), these cases are significant because some Pts may respond well to BRAF/MEK and NTRK inhibitors. Given limited literature…
View article: Regorafenib versus local standard of care in patients with grade 2–3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study)
Regorafenib versus local standard of care in patients with grade 2–3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study) Open
View article: Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience
Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience Open
View article: PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives
PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives Open
Gliomas are the most common primary malignant brain tumours in adults. Despite decades of research into novel therapeutic approaches, the prognosis remains poor. PARP1-2 are critical for DNA repair, cell survival and genomic stability and …
View article: Prolonged response to entrectinib in an adult patient with recurrent glioblastoma harboring a <i>GOPC::ROS1</i> fusion
Prolonged response to entrectinib in an adult patient with recurrent glioblastoma harboring a <i>GOPC::ROS1</i> fusion Open
Data on the use of targeted therapies in glioma are still limited and the identification of useful targetable mutations is still under investigation. Among all the relevant alterations identified through next generation sequencing (NGS) te…
View article: Relationship between glioblastoma location and O6-methylguanine-DNA methyltransferase promoter methylation percentage
Relationship between glioblastoma location and O6-methylguanine-DNA methyltransferase promoter methylation percentage Open
A large literature assessed the relationships between the O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and glioblastoma location with inconsistent results. Studies assessing this association using the percentag…
View article: Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial
Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial Open
Introduction Drug repurposing is a promising strategy to develop new treatments for glioblastoma. In this phase II clinical trial, we evaluated the addition of chlorpromazine to temozolomide in the adjuvant phase of the standard first-line…
View article: Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities
Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities Open
Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor. Standard therapies, including surgical resection, chemoradiation, and tumor treating fields, have not resulted in major improvements in the survival outcom…
View article: Spinal ependymoma in adults: from molecular advances to new treatment perspectives
Spinal ependymoma in adults: from molecular advances to new treatment perspectives Open
Ependymomas are rare glial tumors with clinical and biological heterogeneity, categorized into supratentorial ependymoma, posterior fossa ependymoma, and spinal cord ependymoma, according to anatomical localization. Spinal ependymoma compr…
View article: CTNI-38. RACTAC TRIAL: PHASE II MULTICENTRIC ITALIAN TRIAL ON REPOSITIONING OF THE ANTIPSYCHOTIC DRUG CHLORPROMAZINE AND ITS COMBINATION WITH TEMOZOLOMIDE IN MGMT UNMETHYLATED GLIOBLASTOMA PATIENTS
CTNI-38. RACTAC TRIAL: PHASE II MULTICENTRIC ITALIAN TRIAL ON REPOSITIONING OF THE ANTIPSYCHOTIC DRUG CHLORPROMAZINE AND ITS COMBINATION WITH TEMOZOLOMIDE IN MGMT UNMETHYLATED GLIOBLASTOMA PATIENTS Open
The poor prognosis of patients affected by glioblastoma (GBM) prompts the search for more effective therapies, particularly for GBMs with unmethylated MGMT. Drug repurposing, can represent a safe and inexpensive way to bring novel pharmaco…
View article: P20.06.B SYSTEMIC CHEMOTHERAPY IN ADULT PATIENTS WITH DIFFUSE MIDLINE GLIOMA H3K27-ALTERED
P20.06.B SYSTEMIC CHEMOTHERAPY IN ADULT PATIENTS WITH DIFFUSE MIDLINE GLIOMA H3K27-ALTERED Open
BACKGROUND Adult Diffuse midline glioma (DMG) is a very rare disease. DMGs are currently treated with radiotherapy and temozolomide even if only a few retrospective studies assessed the impact on survival of these approaches. MATERIAL AND …
View article: P17.06.B TARGETED THERAPY MATCHED TO GENOMIC ALTERATIONS (BRAFV600E, NTRK, FGFR, ROS1, PIK3CA, PTEN) IN PATIENTS WITH RECURRENT IDH WILDTYPE GLIOBLASTOMA: A REAL-LIFE COHORT ANALYSIS FROM VENETO INSTITUTE OF ONCOLOGY, PADUA (ITALY)
P17.06.B TARGETED THERAPY MATCHED TO GENOMIC ALTERATIONS (BRAFV600E, NTRK, FGFR, ROS1, PIK3CA, PTEN) IN PATIENTS WITH RECURRENT IDH WILDTYPE GLIOBLASTOMA: A REAL-LIFE COHORT ANALYSIS FROM VENETO INSTITUTE OF ONCOLOGY, PADUA (ITALY) Open
BACKGROUND The use of next-generation sequencing (NGS) allows the identification of subgroups of patients that may respond to personalized targeted therapies (TT). Despite the acquired deep knowledge about biology, there are only a few dat…
View article: OS09.2.A REGORAFENIB IN COMBINATION WITH TEMOZOLOMIDE WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MGMT-METHYLATED, IDH WILDTYPE GLIOBLASTOMA: A PHASE I DOSE-FINDING STUDY (REGOMA-2, EUDRA CT N° 2021-001604-15)
OS09.2.A REGORAFENIB IN COMBINATION WITH TEMOZOLOMIDE WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MGMT-METHYLATED, IDH WILDTYPE GLIOBLASTOMA: A PHASE I DOSE-FINDING STUDY (REGOMA-2, EUDRA CT N° 2021-001604-15) Open
BACKGROUND Glioblastoma (GBM) is associated with the activation of multiple signaling pathways, including the receptor tyrosine kinases, VEGFR, FGFR and PDGFR. The potential response to anti-angiogenic agents makes GBM an attractive target…
View article: P20.14.B SYSTEMIC THERAPY FOR RECURRENT ADULT INTRACRANIAL AND SPINAL EPENDYMOMAS: A MONO-INSTITUTIONAL EXPERIENCE
P20.14.B SYSTEMIC THERAPY FOR RECURRENT ADULT INTRACRANIAL AND SPINAL EPENDYMOMAS: A MONO-INSTITUTIONAL EXPERIENCE Open
BACKGROUND Ependymoma is a rare disease in adult patients (pts) and there is no standard systemic treatment in recurrent disease after surgery and radiotherapy. We reviewed our cases of confirmed intracranial and spinal ependymomas and des…
View article: P17.07.A REGORAFENIB IN RECURRENT GLIOBLASTOMA PATIENTS: AN ITALIAN OBSERVATIONAL, MULTICENTRIC AND PROSPECTIVE TRIAL (REGOMA-OSS)
P17.07.A REGORAFENIB IN RECURRENT GLIOBLASTOMA PATIENTS: AN ITALIAN OBSERVATIONAL, MULTICENTRIC AND PROSPECTIVE TRIAL (REGOMA-OSS) Open
BACKGROUND In the randomized phase 2 REGOMA trial, regorafenib has shown promising activity in recurrent glioblastoma patients with a significantly longer survival compared to the standard lomustine therapy. Subsequently, in Italy regorafe…
View article: P11.60.A RACTAC TRIAL: PHASE II MULTICENTRIC ITALIAN TRIAL ON REPOSITIONING OF THE ANTIPSYCHOTIC DRUG CHLORPROMAZINE AND ITS COMBINATION WITH TEMOZOLOMIDE IN MGMT UNMETHYLATED GLIOBLASTOMA PATIENTS
P11.60.A RACTAC TRIAL: PHASE II MULTICENTRIC ITALIAN TRIAL ON REPOSITIONING OF THE ANTIPSYCHOTIC DRUG CHLORPROMAZINE AND ITS COMBINATION WITH TEMOZOLOMIDE IN MGMT UNMETHYLATED GLIOBLASTOMA PATIENTS Open
BACKGROUND The poor prognosis of patients affected by glioblastoma (GBM) prompts the search for new and more effective therapies, particularly for GBMs with unmethylated MGMT. In this regard, drug repurposing, can represent a safe and inex…
View article: SYST-20 TARGETED THERAPY MATCHED TO GENOMIC ALTERATIONS (BRAFV600E, NTRK, FGFR, ROS1, PIK3CA, PTEN) IN PATIENTS WITH RECURRENT IDH WILDTYPE GLIOBLASTOMA: A REAL-LIFE COHORT ANALYSIS FROM VENETO INSTITUTE OF ONCOLOGY, PADUA (ITALY)
SYST-20 TARGETED THERAPY MATCHED TO GENOMIC ALTERATIONS (BRAFV600E, NTRK, FGFR, ROS1, PIK3CA, PTEN) IN PATIENTS WITH RECURRENT IDH WILDTYPE GLIOBLASTOMA: A REAL-LIFE COHORT ANALYSIS FROM VENETO INSTITUTE OF ONCOLOGY, PADUA (ITALY) Open
We retrospectively analyzed 34 patients (pts) [19 males, 15 females, median age 54] with recurrent IDH wildtype glioblastoma treated with target therapy (TT) based on their next-generation sequencing (NGS) profile, between March2020 and De…
View article: The role of radiation therapy and systemic treatments in meningioma: The present and the future
The role of radiation therapy and systemic treatments in meningioma: The present and the future Open
Meningiomas are the most prevalent tumors of the central nervous system. Their standard treatment is surgery, which can be curative. Adjuvant radiotherapy treatment is reserved for newly diagnosed cases of grade II and grade III meningioma…
View article: Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis
Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis Open
Our study demonstrated the feasibility of NGS in GBM samples. As the number of clinically relevant targets was limited and only a small group of GBM patients were treated with targeted therapy, NGS testing should be performed in the contex…
View article: Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study
Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study Open
View article: Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients
Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients Open
View article: Repurposing chlorpromazine as add-on in the adjuvant phase of first-line glioblastoma therapeutic protocol in patients carrying hypo-/un-methylated<i>MGMT</i>gene promoter: RACTAC, a Phase II multicenter single-arm clinical trial
Repurposing chlorpromazine as add-on in the adjuvant phase of first-line glioblastoma therapeutic protocol in patients carrying hypo-/un-methylated<i>MGMT</i>gene promoter: RACTAC, a Phase II multicenter single-arm clinical trial Open
Background Glioblastoma (GBM) is a devastating brain tumor with poor prognosis, characterized by rapid growth and invasion into surrounding brain tissue. It is a hard-to-treat cancer and represents an unmet medical need. In recent years, t…
View article: Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study
Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study Open
Rechallenge with metronomic TMZ is a well-tolerated option for recurrent GBM, even in pretreated patients. Patients with methylated MGMT disease and good ECOG-PS seem to benefit the most from this treatment.
View article: ANGI-09. BEVACIZUMAB IN ATYPICAL AND ANAPLASTIC MENINGIOMAS: THE BEMEN STUDY
ANGI-09. BEVACIZUMAB IN ATYPICAL AND ANAPLASTIC MENINGIOMAS: THE BEMEN STUDY Open
BACKGROUND the current standard to treat meningiomas can include surgical resection and radiotherapy. Despite the high rate of relapse no systemic treatment is indicated. Few data are available regarding the effectiveness of bevacizumab (B…
View article: BIOM-19. NEXT-GENERATION SEQUENCING (NGS) FOR IDENTIFYING ACTIONABLE MOLECULAR ALTERATIONS IN NEWLY DIAGNOSED AND RECURRENT IDHWT-GLIOBLASTOMA (GBM) PATIENTS: A LARGE MONO INSTITUTIONAL EXPERIENCE
BIOM-19. NEXT-GENERATION SEQUENCING (NGS) FOR IDENTIFYING ACTIONABLE MOLECULAR ALTERATIONS IN NEWLY DIAGNOSED AND RECURRENT IDHWT-GLIOBLASTOMA (GBM) PATIENTS: A LARGE MONO INSTITUTIONAL EXPERIENCE Open
BACKGROUNDNGS panels allow the identification of alterations within hundreds of cancer-related genes and can guide a personalized strategy in glioma treatment. METHODS From Nov 2019 to Jan 2022 at Veneto Institute of Oncology, Padua, Italy…